Insulin treatment and state of control before, during, and after connection to a glucose controlled insulin infusion system (Biostator).
Nine insulin-dependent, juvenile-onset diabetics were treated for more than twenty four hours with an artificial beta cell (Biostator). Using the amounts and profile of the insulin delivered by the machine as a guide for subsequent subcutaneous therapy, a better state of control was obtained. However, with the algorithm constants used, we found the Biostator to deliver more insulin (average 36%) than needed for subcutaneous therapy. Repeated oral glucose tolerance tests show that constants used in the algorithms might be optimized.
D000293:Adolescent; D000328:Adult; D001187:Artificial Organs; D001786:Blood Glucose / Q000032:analysis*; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy*; D005246:Feedback; D005951:Glucose Tolerance Test; D006801:Humans; D007263:Infusions, Parenteral; D007328:Insulin / Q000008:administration & dosage / Q000627:therapeutic use*; D007515:Islets of Langerhans / Q000378:metabolism*; D008875:Middle Aged
D001786:Blood Glucose; D007328:Insulin